MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 14, 2005; DOI: 10.1124/mol.105.012807


0026-895X/05/6803-840-846$20.00
Mol Pharmacol 68:840-846, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.012807v1
68/3/840    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ranatunga, K. M.
Right arrow Articles by Williams, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ranatunga, K. M.
Right arrow Articles by Williams, A. J.

The Gln4863Ala Mutation within a Putative, Pore-Lining Trans-Membrane Helix of the Cardiac Ryanodine Receptor Channel Alters Both the Kinetics of Ryanoid Interaction and the Subsequent Fractional Conductance

Kishani M. Ranatunga, Tracy M. Moreno-King, Bhavna Tanna, Ruiwu Wang, S. R. Wayne Chen, Luc Ruest, William Welch, and Alan J. Williams

Myocardial Systems Biology Group, National Heart and Lung Institute, Imperial College London, London, United Kingdom (K.M.R., T.M.M.-K., B.T., A.J.W.); Cardiovascular Research Group, Departments of Physiology and Biophysics and of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada (R.W., S.R.W.C.); Department of Chemistry, University of Sherbrooke, Sherbrooke, Quebec, Canada (L.R.); and 145 Howard Medical Sciences, Department of Biochemistry/330, University of Nevada, Reno, Nevada (W.W.)

The specific, high-affinity interaction of the plant toxin ryanodine with its molecular target the ryanodine receptor channel (RyR) has been instrumental in RyR research. Alanine scanning of putative pore regions of mouse RyR2 has highlighted the amino acid Gln4863, predicted to lie within trans-membrane helix TM10, as an important determinant of ryanodine binding. We have investigated the effects of several ryanodine derivatives, guanidinopropionylryanodine, 21-p-nitrobenzoylamino-9{alpha}-hydroxyryanodine, 8{beta}-amino-9{alpha}-hydroxyryanodine, and 21-amino-9{alpha}-hydroxyryanodine, with the mouse Q4863A RyR2 mutant at the single-channel level. Our results demonstrate that the rate of dissociation of all ryanoids investigated is increased by the mutation. The modification of channel function after ryanoid binding is qualitatively similar for wild-type and mutant, but in several cases, single-channel conductances were increased with Q4863A. These novel findings have been interpreted within the framework of existing comparative molecular field analysis studies on ryanoids. We suggest that replacement of a glutamine by an alanine residue at position 4863 causes RyR2 to simultaneously alter interactions with both ends of the ryanoid molecule.


Received March 11, 2005; accepted June 14, 2005

Address correspondence to: Dr. Alan J. Williams, Myocardial Systems Biology Group, National Heart and Lung Institute, Guy Scadding Building, Imperial College London, London SW3 6LY, United Kingdom. E-mail: a.j.williams{at}imperial.ac.uk




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
B. Tanna, W. Welch, L. Ruest, J. L. Sutko, and A. J. Williams
The Interaction of an Impermeant Cation with the Sheep Cardiac RyR Channel Alters Ryanoid Association
Mol. Pharmacol., June 1, 2006; 69(6): 1990 - 1997.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics